#None #Nutraceutical #Aventura #Osteoporosis #Bone-Viva

Introduction

A pivotal study recently published in The European Journal Of Medicine shines a light on a breakthrough nutraceutical, Bone-Viva, designed specifically for women suffering from osteoporosis and osteopenia. Osteoporosis affects more than 10 million Americans, while roughly 43 million experience low bone mass, making this research particularly significant.

Study Overview

The research, conducted by the esteemed Dr. Norman B. Gaylis, M.D., at the Arthritis and Rheumatic Disease Specialties clinic in Aventura, Florida, represents what is considered the first documented exploration of a nutraceutical's effects featured in a medical journal. Dr. Gaylis co-authored an article titled "Effectiveness of a Nutraceutical, Bone-Viva®, which is Composed of Generally Recognized as Safe (GRAS) Approved Ingredients in Stabilizing and Improving Bone Mineral Density in Patients with Osteopenia and Osteoporosis."

For 18 months, the study assessed the impact of Bone-Viva on women aged 50 and above who were diagnosed with either condition. The participants were divided into groups receiving various treatments, including Bone-Viva alone, denosumab, romosozumab, and a combination of Bone-Viva with established pharmaceutical therapies.

Breakthrough Findings

The results gleaned from the study were remarkable. Dr. Gaylis highlighted that Bone-Viva not only stabilizes but also improves bone mineral density (BMD) in patients, showcasing its effectiveness.

• - Lumbar Spine: The combination therapy group demonstrated the most significant enhancement in T-scores (+0.20), exceeding other groups such as denosumab (+0.18) and romosozumab (+0.12). Improvement rates showed that 60-65% for combination therapy and denosumab, 48% for romosozumab, and 42% for Bone-Viva.

• - Femoral Neck: Bone-Viva exhibited the highest stability rate at 60%, while other therapies showed slight shifts in bone density.

• - Total Hip: All treatment groups reported minor yet consistent gains, with the combination therapy leading at +0.17.

Dr. Gaylis noted, "These findings are groundbreaking because very few nutraceutical studies are published in scientific journals supporting the product. The research underscores the urgency to diagnose and treat osteopenia and osteoporosis effectively, particularly as traditional treatments can be burdensome and carry notable side effects."

Ingredients and Mechanism

Bone-Viva is crafted with an innovative, patent-pending formulation aimed at fostering bone metabolism and enhancing skeletal strength.

Unlike traditional pharmacotherapy, Bone-Viva offers a natural, nutrient-driven method targeting crucial pathways involved in bone remodeling and collagen synthesis. Its formula includes diverse bioactive ingredients known for their roles in bone health, such as Boron, Silicon, Manganese, Zinc, Copper, Vitamin D3, Vitamin K2, Strontium, Curcumin, and Beta-Caryophyllene, all of which are Generally Recognized as Safe (GRAS) approved.

Future Implications

This noteworthy investigation not only provides promising prospects for patients unwilling to pursue conventional treatments but also emphasizes the importance of developing innovative approaches to manage bone health issues effectively. Patients suffering from these conditions often face challenges stemming from inadequate diagnosis and treatment, making Bone-Viva's viable alternative invaluable.

Conclusion

In light of this groundbreaking study, Bone-Viva emerges as a pivotal treatment strategy for women battling osteoporosis and osteopenia. As Dr. Gaylis continues to be at the forefront of rheumatology, he expresses hope for future advancements in nutraceutical research, signifying a notable shift in how osteoporotic conditions may be treated moving forward. Those who wish to delve deeper into the study or arrange an interview with Dr. Gaylis can contact Rhonda Price at [email protected].